Quentis Therapeutics’ $48 Million Series A Financing Round

Goodwin advised Quentis Therapeutics in the deal

Quentis Therapeutics Inc., completed a $48 million Series A financing co-led by founding investor Versant Ventures and by Polaris Partners and the affiliated LS Polaris Innovation Fund. The syndicate also included AbbVie Ventures, Taiho Pharmaceutical Co., Ltd., Yonghua Capital, Alexandria Venture Investments and New York Ventures, the investment arm of Empire State Development.

Quentis is pioneering first-in-class cancer immunotherapies that modulate endoplasmic reticulum (ER) stress response pathways in the tumor microenvironment. The Series A proceeds will support the advancement of Quentis’ lead program, a small molecule IRE1? inhibitor, into the clinic in 2019 and through clinical proof-of-concept. Additional uses of the capital include developing a pipeline of preclinical programs and building out Quentis’ team.

Quentis Therapeutics is a preclinical stage biotechnology company that is translating novel biology into new therapeutic approaches to help more cancer patients benefit from immunotherapy. The company, led by Michael Aberman and Joseph Vacca, is based in NY.

The Goodwin team was led by partner Kingsley Taft (Picture) and colleagues Mulon Luo and Ryan LaForce, and included associates Brett Burka and Jake Hays.

Involved fees earner: Kingsley Taft – Goodwin Procter; Mulon Luo – Goodwin Procter; Ryan LaForce – Goodwin Procter; Brett Burka – Goodwin Procter;

Law Firms: Goodwin Procter;

Clients: Quentis Therapeutics Inc.;


Author: Ambrogio Visconti